Late last year, the FDA issued a warning against the use of the injectable form of dolasetron mesylate (Anzemet) to prevent nausea and vomiting in patients undergoing cancer chemotherapy in light of new data indicating the drug can cause life-threatening cardiac arrhythmias. The FDA indicated that Anzemet may still be given orally to chemotherapy patients, or injected at lower doses following surgery to prevent postoperative nausea and vomiting.
Patients at particular risk from Anzemet are those with underlying heart conditions or those who have existing heart rate or rhythm problems.
